Shares of Lannett Company, Inc. (NYSE:LCI) ended Wednesday session in red amid volatile trading. The shares closed down -1.20 points or -5.16% at $22.05 with 693,171 shares getting traded. Post opening the session at $23.15, the shares hit an intraday low of $21.85 and an intraday high of $23.55 and the price vacillated in this range throughout the day.
Market Cap/Outstanding Shares
The company has a market cap of $782.24 million and the number of outstanding shares have been calculated to be 37.00 million shares.
Performance weekly/monthly/quarterly/yearly in percentage (%)
The performance for the week is valued at 8.62%, resulting in a performance for the month at -3.50%. Therefore, the stated figure displays a quarterly performance of -27.92% and an annual performance of -38.72%.traded up -5.16% on 16 November, 2016 hitting $22.05.
EPS (Earning Per Share )
The EPS of LCI is strolling at -0.49, measuring its EPS growth this year at -70.30%. As a result, the company has an EPS growth of -5.26% for the approaching year. Company’s EPS for the past five years is valued at 159.60%, leading it to an EPS value of 10.64% for the next five years.
Lannett Company, Inc. has a P/S value of 1.19, measuring P/B at 1.53. Its P/Cash is valued at 2.93 and P/FCF is at 5.82.
Beta factor is stands at 2.29 and Avg. true range is 1.78. Historically, the volatility of this stock is about 7.72% a week and 8.35% a month.
Lannett Company, Inc. (LCI) recently declared that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, the therapeutic equivalent to the reference listed drug, Namenda Tablets, 5 mg and 10 mg, of Forest Laboratories LLC. According to IMS, total U.S. sales in 2015 of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, at Average Wholesale Price (AWP) were about $50 million.
“Memantine Hydrochloride Tablets is indicated for the treatment of moderate to severe dementia,” said Arthur Bedrosian, chief executive officer of Lannett. “This product is in addition to our Memantine Oral Solution and represents the ninth product approval we have received in calendar 2016. We expect to begin marketing the product in about two months.”